Tuesday, August 29, 2006 13:00 IST Stockholm, Sweden
Diamyd Medical has announces that its lead drug candidate, Diamyd, has demonstrated overall statistically significant efficacy in preserving insulin production in a phase II clinical trial in 70 children and adolescents with type 1 diabetes.
